|
Name |
Terpestacin C
|
Molecular Formula | C25H42O4 | |
IUPAC Name* |
(1R,3E,5S,8E,12E,15S,16S,17R,18R)-18-[(2S)-1-hydroxypropan-2-yl]-4,8,12,15-tetramethylbicyclo[13.3.0]octadeca-3,8,12-triene-5,16,17-triol
|
|
SMILES |
C/C/1=C\CC/C(=C/C[C@]2([C@H](C/C=C(/[C@H](CC1)O)\C)[C@@H]([C@H]([C@H]2O)O)[C@H](C)CO)C)/C
|
|
InChI |
InChI=1S/C25H42O4/c1-16-7-6-8-17(2)13-14-25(5)20(11-10-18(3)21(27)12-9-16)22(19(4)15-26)23(28)24(25)29/h7,10,13,19-24,26-29H,6,8-9,11-12,14-15H2,1-5H3/b16-7+,17-13+,18-10+/t19-,20-,21+,22+,23-,24-,25+/m1/s1
|
|
InChIKey |
LTSFUUJKRVARPQ-BUHJFDRHSA-N
|
|
Synonyms |
Terpestacin C
|
|
CAS | NA | |
PubChem CID | 156582439 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 406.6 | ALogp: | 2.9 |
HBD: | 4 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 80.9 | Aromatic Rings: | 2 |
Heavy Atoms: | 29 | QED Weighted: | 0.5 |
Caco-2 Permeability: | -4.625 | MDCK Permeability: | 0.00005390 |
Pgp-inhibitor: | 0.94 | Pgp-substrate: | 0.995 |
Human Intestinal Absorption (HIA): | 0.977 | 20% Bioavailability (F20%): | 0.574 |
30% Bioavailability (F30%): | 0.699 |
Blood-Brain-Barrier Penetration (BBB): | 0.813 | Plasma Protein Binding (PPB): | 91.10% |
Volume Distribution (VD): | 0.892 | Fu: | 5.10% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.12 |
CYP2C19-inhibitor: | 0.013 | CYP2C19-substrate: | 0.308 |
CYP2C9-inhibitor: | 0.011 | CYP2C9-substrate: | 0.522 |
CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.189 |
CYP3A4-inhibitor: | 0.094 | CYP3A4-substrate: | 0.173 |
Clearance (CL): | 7.251 | Half-life (T1/2): | 0.792 |
hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.133 |
Drug-inuced Liver Injury (DILI): | 0.011 | AMES Toxicity: | 0.001 |
Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.979 |
Skin Sensitization: | 0.942 | Carcinogencity: | 0.015 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.647 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003560 | 0.576 | D0Z1FX | 0.269 | ||||
ENC002974 | 0.576 | D08SVH | 0.250 | ||||
ENC001882 | 0.576 | D0T2PL | 0.250 | ||||
ENC006130 | 0.512 | D05BTM | 0.240 | ||||
ENC003210 | 0.491 | D03DXN | 0.239 | ||||
ENC005683 | 0.440 | D08QMX | 0.239 | ||||
ENC004253 | 0.425 | D0Y7LD | 0.238 | ||||
ENC003502 | 0.408 | D0S0NK | 0.237 | ||||
ENC005684 | 0.386 | D0OR2L | 0.236 | ||||
ENC003463 | 0.385 | D02ZGI | 0.231 |